High-grade relapsed chemotherapy- and immunotherapy-naive tumors of both luminal and basal molecular subtypes were intensely infiltrated by immune CD8+ cells: T-suppressors occupied 24.9 ± 1.3% and 24.1 ± 1.0% of the tumor area, respectively, while CD8+ expression in low-grade tumors was 13.4 ± 1.2% for luminal subtype (p = 0.002 in comparison with high-grade GATA3-positive NMIBC) and 19.5 ± 1.3% for basal one. The gene discussed is CD8A; the disease is neoplasm.